Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 9/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 6/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26419389 | 1.00 | AHR (0.64) | AHRKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL26419395 | 1.00 | AHR (0.64) | AHRKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL26089047 | 0.88 | AHR (0.70) | AHRLMNANLRP3CNR2CNR1 | |
| SCHEMBL26086751 | 0.88 | AHR (0.70) | AHRLMNANLRP3CNR2CNR1 | |
| SCHEMBL26089802 | 0.88 | AHR (0.64) | AHRRAB9A | |
| SCHEMBL26088624 | 0.88 | AHR (0.64) | AHRRAB9A | |
| SCHEMBL26087025 | 0.88 | AHR (0.70) | AHRLMNANLRP3CNR2CNR1 | |
| SCHEMBL26086628 | 0.87 | AHR (0.63) | AHRKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL26088439 | 0.87 | AHR (0.63) | AHRKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL26086770 | 0.85 | AHR (0.63) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037322-B2 | AHR agonists | ELI LILLY AND COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230127797-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037322-B2 | AHR agonists | AHR, ARNT, RORC | AHR 1/4885KDM4E 1656/4885NPC1 1273/4885 |
| US-20230127797-A1 | AHR AGONISTS | AHR, ARNT, RORC | AHR 1/4885KDM4E 1656/4885NPC1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.